AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

Shots:

• The submission is based on two P-III studies KEEPsAKE-1 & -2 studies involves assessing Skyrizi (150mg) vs PBO in adult patients with active PsA who had an inadequate response or intolerant to biologic therapy and/or non-biologic DMARDs respectively
• The 1EP and 2EP of both studies showed ACR20 response @24wks., improvements in disease activity, skin clearance, 90% improvement in PASI 90 & physical function as measured by HAQ-DI
• The safety profile was generally consistent with the known profile of Skyriz in psoriasis patients, with no new safety risks observed. Skyrizi is an IL-23 inhibitor, being developed in collaboration with Boehringer Ingelheim

Click here to­ read full press release/ article | Ref: Abbvie | Image: The Street